Industry Categories News Contact Us

Iterum to conduct trials for oral Sulopenem in uncomplicated UTIs

Author : Ojaswita Kutepatil | Published Date : 2018-08-11 

Pharmaceutical giant Iterum Therapeutics plc, which develops medications for infections caused by multi-drug resistance pathogens, has recently announced its clinical trial for Sulopenem. Sources state that this would mark the first phase of its Phase 3 clinical trials.

For the uninitiated, Sulopenem works well during in-vitro activity to fight organisms commonly concerned with urinary tract and intra-abdominal infections. According to reliable sources, in the trial known as Sulopenem for Resistant Enterobacteriaceae (Sure) 1, the oral sulopenem will be compared to oral ciprofloxacin in women down with uncomplicated urinary tract infections (uUTI).

Sulopenem is Iterum’s lead compound and new antibiotic meant to cure gram-negative and multi-drug resistant infections. 

As per a news release by Iterum, patients infected with quinolone resistant pathogen may need secondary antibiotic prescription or hospitalization, if quinolone is prescribed for uncomplicated UTI. Among U. S patients, resistance to fluoroquinolone has been observed in over 20% of isolates from urinary tract caused primarily by resistance to E. coli and P.mirabilis.

The growth of UTIs with multi-drug resistance is disturbing and current drugs fail in treatment, claimed Iterum’s M.D. and Chief Scientific Officer, Michael Dunne. Resistance to fluoroquinolones is rising and healthcare professionals urgently need new oral options to treat infections such as UTIs, he further added.

FDA has warned about the usage of fluoroquinolones for uUTI patients who can be prescribed other drugs as well, as it poses more risks than benefits, stated Dunne.

Approximately 1,364 patients are expected to enroll for the study conducted under an agreement of Special Protocol Assessment (SPA) from the FDA. The trial process will be carried out with patients receiving either oral sulopenem twice for five days or oral ciprofloxacin twice for three days, the ideal uUTI dosage.

Incidentally, Iterum is in talks for initiating two additional Phase 3 clinical trials that will examine the use of oral and intravenous sulopenem in complicated UTIs and complicated intra abominable infections, reported sources familiar with the trials.

About Author

Ojaswita Kutepatil

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, worked as a BDE and Technical Engineer before switching her profession to content writing. Currently, she works at AlgosOnline. as an Content writer, where she pens down write-ups pertaining to the market research industry. Crafting, reading, and music are some of her other areas of interest.

She can be contacted at- [email protected] | https://twitter.com/ojaswita_k

Related News

Siemens Gamesa unveils its first-ever 10MW offshore wind turbine

Published Date: 2019-01-18         Author: Ojaswita Kutepatil

The new wind turbine’s nacelles are expected to be initially manufactured at SGRE’s factory in Germany’s Cuxhaven. Siemens Gamesa Renewable Energy (SGRE), a renewable energy industry leader headquartered in Spain, has reportedly unveiled its latest SG 10.0-193 DD, the company&rs... Read More

Rubrik Inc., raises $261 million in the latest Series E funding round

Published Date: 2019-01-16         Author: Ojaswita Kutepatil

Rubrik has raised up to USD 553 million in funds so far, including the Series E round. Rubrik Inc., a data management company based in California, USA, has reportedly secured as much as US$ 261 million in Series E funding, the latest financing round of the company led by Bain Capital Ventures, a ... Read More

American Express buys Japanese restaurant booking app Pocket Concierge

Published Date: 2019-01-16         Author: Ojaswita Kutepatil

The service was reportedly launched in 2013 to help customers book quality restaurants that have months-long waiting lists for reservations.   The company currently works with more than 800 restaurants and has made available its app in English, Japanese and Chinese. U.S. card issuer... Read More

© 2019 Fractovia. All Rights Reserved